AMRUTAJAN HEALTH LTD
AMRUTANJAN · General/Diversified · NSE
₹572
Current Market Price
Fair Value (DCF)
₹308
Margin of Safety
-46.1%
Updated 2d ago
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
78%
ROE
—
Debt/Equity
0.01
WACC
11.1%
Market Cap
₹1,653 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
20.6%
Return on capital employed
EV / EBITDA
21.4×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
315.2×
EBIT covers interest
Current Ratio
3.44×
Short-term liquidity
Asset Turnover
1.07×
Revenue per ₹ of assets
Revenue CAGR (3Y)
3.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹572.05
Bear case
₹192.31
MoS -197.5%
Base case
₹308.12
MoS -85.7%
Bull case
₹379.16
MoS -50.9%
Ratio Trends
AMRUTANJAN · last 8 annual periods
ROE
15.6%
ROCE
23.1%
Operating Margin
—
Debt / Equity
0.01×
PE
131.1×
EV / EBITDA
28.2×
Historical Financials
AMRUTANJAN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2020 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹261 Cr | ₹406 Cr | ₹100 Cr | ₹127 Cr | ₹451 Cr | +14.6% |
| EBITDA | — | ₹94.9 Cr | ₹58.9 Cr | ₹68.2 Cr | ₹75.9 Cr | -5.4% |
| EBIT | ₹34.7 Cr | ₹91.1 Cr | ₹16.5 Cr | ₹19.7 Cr | — | -13.2% |
| PAT | ₹25.1 Cr | ₹67.2 Cr | ₹12.7 Cr | ₹13.7 Cr | ₹50.8 Cr | +19.3% |
| EPS (diluted) | ₹8.58 | ₹23.03 | ₹4.34 | ₹4.72 | — | -13.9% |
| CFO | — | ₹53.2 Cr | ₹19.2 Cr | ₹27.9 Cr | ₹50.9 Cr | -1.1% |
| CapEx | — | — | — | — | ₹-35.6 Cr | — |
| FCF | — | — | — | — | ₹15.3 Cr | +0.0% |
| Total Assets | — | ₹350 Cr | ₹362 Cr | ₹367 Cr | ₹421 Cr | +4.8% |
| Total Debt | — | — | ₹0.0 Cr | ₹0.0 Cr | ₹2.1 Cr | — |
| Shareholders' Equity | — | — | ₹291 Cr | ₹288 Cr | ₹327 Cr | +2.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AMRUTANJAN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| VENUSREM VENUS REMEDIES LIMITED | +17.4% | 40 | Below Fair Value | 8.1% | — |
| BETA BETA DRUGS LIMITED | -29.3% | 28 | Above Fair Value | 21.5% | — |
| WINDLAS WINDLAS | — | — | Pending | 12.1% | — |
| SYNCOMF SYNCOM FORMU (I) LTD | -20.2% | 31 | Above Fair Value | 14.4% | — |
| SAKAR SAKAR HEALTHCARE LIMITED | -76.9% | 25 | Data Limited | 6.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for AMRUTANJAN in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. AMRUTAJAN HEALTH LTD (AMRUTANJAN.NS) trades at 572.05 vs a model fair value of 308.12, a gap of -46.1%. Piotroski F-score: 5/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AMRUTANJAN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AMRUTANJAN →
Compare
Head-to-head with peers
Compare AMRUTANJAN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AMRUTANJANNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.